Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07734077) titled 'Revumenib in Patients With Myelofibrosis' on July 24.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: John Mascarenhas
Condition:
Myelofibrosis
Post-polycythemia Vera Myelofibrosis
Post-essential Thrombocythemia Myelofibrosis
Intervention:
Drug: Revumenib
Drug: Ruxolitinib
Drug: FEDRATINIB
Recruitment Status: Not recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: December 1, 2026
Target Sample Size: 32
Countries of Recruitment:
United States
To know more, vis...